INSULIN DETEMIR clinical trials

Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes as add on to once-daily basal insulin with or without metformin

This study is looking at a new combination medicine, CagriSema, for people with type 2 diabetes. We want to see how well it helps control blood sugar and manage weight, alongside their usual insulin and other diabetes medicines.